Rallybio has dosed the first subject in a trial of a potential treament for foetal and neonatal alloimmune thrombocytopaenia (FNAIT).

Being realistic, responsive and transparent is key in engaging unresponsive and underperforming clinical trial sites; that ...

Trump's tariffs will not only impact sponsors, but higher costs will ripple down the clinical trial supply chain in the US.

The trial will see healthy volunteers infected with dengue to test the impact of AbViro’s monoclonal antibody therapy.

Nerandomilast is posed to be Boehringer Ingelheim’s successor to its blockbuster Ofev (nintedanib)in IPF and PPF.

Historical epidemiological analysis has demonstrated an association between urbanisation and growing cancer burden across the ...

Palvella Therapeutics is set to expand Phase III SELVA trial to include subjects aged three to five years old.

Q32 Bio has stopped a Phase II trial of its former lead renal disease candidate as it focuses on its alopecia areata ...

BMS has reported that the Phase II TRANSCEND FL trial assessing Breyanzi, met its primary endpoint in the marginal zone ...

Radiopharm Theranostics’ RAD 101 imaging molecule identified brain tumours in all 12 treatment-naïve patients in a ...

Regeneron has reported positive outcomes from the Phase III trial of Eylea HD in treating individuals with macular oedema ...

Cyclo Therapeutics’ Trappsol Cyclo was able to induce clinical improvement in seven out of eight children with Neimann-Pick ...